OOIR: Observatory of International Research

Papers

(The median citation count of International Journal of Gynecological Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma	1035
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*	138
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer	98
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-1	74
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors	69
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program	68
Human papillomavirus-independent cervical cancer	60
Evaluating meaningful levels of financial toxicity in gynecologic cancers	57
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery	56
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer	55
Management of pregnancy in women with cancer	54
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023	52
Uterine serous carcinoma: key advances and novel treatment approaches	47
Advances in immunotherapy for cervical cancer: recent developments and future directions	46
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment follo	44
SUCCOR cone study: conization before radical hysterectomy	42
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification	42
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001	40
Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer	38
Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management	37
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)	33
Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer	32
Ultrastaging methods of sentinel lymph nodes in endometrial cancer – a systematic review	30
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?	29
Endometrial carcinosarcoma	29

Imaging modalities in pregnant cancer patients	28
Updates in the treatment of vaginal cancer	27
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis	27
A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer	26
Neoadjuvant chemotherapy followed by surgery in cervical cancer: past, present and future	26
Magnetic resonance imaging-radiomics in endometrial cancer: a systematic review and meta-analysis	25
Updates on cervical cancer prevention	25
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer	24
Proportions and incidence of locally advanced cervical cancer: a global systematic literature review	24
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)	23
Impact of hypoxia on cervical cancer outcomes	23
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020	22
Immunotherapy in endometrial cancer	21
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the Eu	21
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovar	21
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the E	21
Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers	20
Long-term survival outcomes in high-risk endometrial cancer patients undergoing sentinel lymph node biopsy alone versus lymphadenectomy	20
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)	20
The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review	20
Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation	20
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance	20
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study	19
Urinary diversion after pelvic exenteration for gynecologic malignancies	19
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma	18
Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis	18
Fertility preservation in patients with BRCA mutations or Lynch syndrome	18
Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review	18
Neoadjuvant chemotherapy prior to fertility-sparing surgery in cervical tumors larger than 2 cm: a systematic review on fertility and oncologic outcomes	18
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 va	18
Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers	17
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?	17
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions	17
Enhanced recovery after minimally invasive gynecologic oncology surgery to improve same day discharge: a quality improvement project	17
European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma	17
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer	17
Fertility and pregnancy outcome in gestational trophoblastic disease	16
Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study	16
FIGO 2023 endometrial cancer staging: too much, too soon?	16
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study	16
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEG	15
The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma	15
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for plati	15
Long-term quality of life outcomes of women treated for early-stage endometrial cancer	15
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)	14
Refusal of surgery and survival outcomes in endometrial cancer	14
Biomarker-driven therapy in endometrial cancer	14
Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer	14
Image-guided brachytherapy in cervical cancer including fractionation	14
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma	14

Low-grade serous ovarian cancer: expert consensus report on the state of the science	14
Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking	14
Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer	14
Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors	14
Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER)	14
Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm	13
Oncologic and obstetric outcomes after simple conization for fertility-sparing surgery in FIGO 2018 stage IB1 cervical cancer	13
Integrating antibody drug conjugates in the management of gynecologic cancers	13
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation	13
Cervical conization and lymph node assessment for early stage low-risk cervical cancer	13
Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial)	13
Safety and management of niraparib monotherapy in ovarian cancer clinical trials	12
FIGO 2018 stage IB endocervical adenocarcinomas: an international study of outcomes informed by prognostic biomarkers	12
Uterine transposition after radical trachelectomy	12
Endometrial stripe thickness: a preoperative marker to identify patients with endometrial intraepithelial neoplasia who may benefit from sentinel lymph node mapping and biopsy	12
Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study	12
Gastric-type adenocarcinoma of the cervix in patients with Peutz-Jeghers syndrome: a systematic review of the literature with proposed screening guidelines	12
Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research a	12
Simplified anatomical nomenclature of lateral female pelvic spaces	12
Conization and lymph node evaluation as a fertility-sparing treatment for early stage cervical cancer	11
Primary mucinous ovarian cancer: options for surgery and chemotherapy	11
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline	11
Longitudinal patient-reported outcomes and restrictive opioid prescribing after minimally invasive gynecologic surgery	11
Uterine transposition for gynecological cancers	11
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series	11
Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size <2 cm: a systematic review and meta-analysis	11
The role of radiotherapy in ovarian cancer	11
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study	11
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis	11
Incorporating molecular profiling into endometrial cancer management requires prospective studies	11
Quality assurance in human papillomavirus testing for primary cervical screening	11
Advances in immunotherapy in cervical cancer	11
Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study	11
The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer	10
Avascular spaces in radical hysterectomy	10
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol	10
The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety	10
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected	10
Metronomic oral cyclophosphamide in relapsed ovarian cancer	10
Prognostic factors in locally advanced cervical cancer with pelvic lymph node metastasis	10
Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis	10
Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer	10
Molecular subclassification of vulvar squamous cell carcinoma: reproducibility and prognostic significance of a novel surgical technique	10
Human papillomavirus (HPV) vaccination: a call for action in Italy	10
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)	10
Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study	10
Detection of microRNA in urine to identify patients with endometrial cancer: a feasibility study	10
Sentinel lymph node detection in early-stage ovarian cancer: a systematic review and meta-analysis	10
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer	10
Uterine transposition in a pre-pubertal patient	9
Placenta accreta spectrum: a non-oncologic challenge for gynecologic oncologists	9
Novel therapeutics in low-grade serous ovarian cancer	9
Sleep and gynecological cancer outcomes: opportunities to improve quality of life and survival	9
Uterine transposition for fertility and ovarian function preservation after radiotherapy	9
ESGO/ESTRO quality indicators for radiation therapy of cervical cancer	9
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose	9
The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries	9
Inside the war: life in Ukraine	9
Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE)	9
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis	9
Role of stereotactic body radiotherapy in gynecologic radiation oncology	9
Impact of SARS-CoV-2 on training and mental well-being of surgical gynecological oncology trainees	9
Fertility considerations prior to conservative management of gynecologic cancers	9
Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study	9
Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups	9
Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study	9
ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer	9
Long-term response to olaparib inBRCA1-related ovarian cancer with brain metastases	9
Peritoneal carcinomatosis after minimally invasive surgery versus open radical hysterectomy: systematic review and meta-analysis	9
Fertility sparing surgery in sex-cord stromal tumors: oncological and reproductive outcomes	9
Radical trachelectomy	9
Update in the molecular classification of endometrial carcinoma	9
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer	8
Oncologic outcomes of surgical para-aortic lymph node staging in patients with advanced cervical carcinoma undergoing chemoradiation	8
Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States	8
Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials	8
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study	8
Risk of second malignancy in patients with ovarian clear cell carcinoma	8
Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)	8
Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer	8

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3	8
Fertility-sparing surgery for patients with stage IC2 or IC3 epithelial ovarian carcinoma: any evidence of safety?	8
Outcomes of comprehensive lymphadenectomy for patients with advanced stage ovarian carcinoma and rare histologic sub-types	8
Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States	8
Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators	8
Gender imbalance in gynecologic oncology authorship and impact of COVID-19 pandemic	8
Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review	8
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer	8
Myeloid neoplasms post PARP inhibitors for ovarian cancer	8
Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients	8
Overcoming PARP inhibitor resistance in ovarian cancer	8
Predictive factors of sentinel lymph node failed mapping in endometrial carcinoma patients: a systematic review and meta-analysis	8
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer	8
Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO)	7
Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation	7
The modified 5-item frailty index is a predictor of post-operative complications in vulvar cancer: a National Surgical Quality Improvement Program (NSQIP) analysis	7
Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study)	7
Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review	7
Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer	7
Disparity of ovarian cancer survival between urban and rural settings	7
Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer	7
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study	7
Gynecologic oncologists in surgery for placenta accreta spectrum: a survey for practice, experience, and interest	7
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study	7
Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or	7
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase	7
Interobserver and intraobserver variability of RECIST assessment in ovarian cancer	7
Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis	7
Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer	7
Impact of surgical approach on prevalence of positive peritoneal cytology and lymph-vascular invasion in patients with early-stage endometrial carcinoma: a National Cancer Database study	7
New therapies for clear cell ovarian carcinoma	7
Transvaginal natural orifice transluminal endoscopic surgery (VNOTES) total retroperitoneal sentinel lymph node biopsy for an endometrial cancer patient with prior colon cancer surgery	7
Lymphadenectomy for early-stage mucinous ovarian carcinoma	7
Consensus on the Gemelli terminology of surgical anatomy for radical hysterectomy	7
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a proj	7
Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting	7
Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study	6
Employment disruption among women with gynecologic cancers	6
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report	6
Efficacy of pre-operative pharmacologic thromboprophylaxis on incidence of venous thromboembolism following major gynecologic and gynecologic oncology surgery: a systematic review and meta-analysis	6
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study	6
Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer	6
A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary	6
Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a Latin-American multicenter study	6
Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?	6
A prospective randomized controlled trial evaluating the safety and efficacy of patient blood management program in patients with gynecologic cancer (KGOG 4011/PBM)	6
BRCAstatus and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score	6
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials	6
Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study	6
Social media ambassadors and collaboration with OncoAlert: a European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022	6
Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer	6
Improvement in radiation techniques for locally advanced cervical cancer during the last two decades	6
Oncological safety of hysteroscopy in endometrial cancer	6
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study	6
Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee	6
Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population	6
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study	6
Survival effect of intra-operative tumor spillage during minimally invasive hysterectomy for early-stage endometrial cancer: a call for research	6
Ghost ileostomy: prevention, diagnosis, and early treatment of colorectal anastomosis leakage in advanced ovarian cancer	6
Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis	6
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis	6
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma	6
Factors impacting length of stay and survival in patients with advanced gynecologic malignancies and malignant bowel obstruction	6
Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States	6
Management of ovarian masses in pregnancy: patient selection for interventional treatment	6
Fertility preservation in rare ovarian tumors	6
Radiation oncology management of stage III and IVA cervical carcinoma	6
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group	6
Uterine smooth muscle tumors with uncertain malignant potential: analysis following fertility-saving procedures	6
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocol	6
Colorectal cancer ovarian metastases	5
Secondary malignancies in long-term ovarian cancer survivors: results of the ‘Carolin meets HANNA’ study	5
Imaging modalities in fertility preservation in patients with gynecologic cancers	5
Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry	5
Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists	5
Impact of gynecological cancers on health-related quality of life: historical context, measurement instruments, and current knowledge	5
Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma	5
The role of oncovascular surgery in gynecologic oncology surgery	5
Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery	5
Surgical staging, the meaning of life, and other existential ponderings	5
Ovarian yolk sac tumor	5
Sentinel lymph node mapping in early-stage ovarian cancer: surgical technique in 10 steps	5
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery	5
Uterus transplantation for fertility preservation in patients with gynecologic cancer	5
Use of an artificial mammary implant in total pelvic exenteration	5
Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery	5
Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian cancer	5
Cervical cancer in pregnancy at various gestational ages	5
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients	5
Growing teratoma syndrome	5
¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) predictive score for complete resection in primary cytoreductive surgery	5
Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population	5
Facilitated cascade testing (FaCT): a randomized controlled trial	5
Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somaticCTNNB1mutation on recurrence-free survival	5
Can the Tilburg Frailty Indicator predict post-operative quality of recovery in patients with gynecologic cancer? A prospective cohort study	5